SCHEMBL20873282

SCHEMBL20873282

COc1ccc(N2CCN(CC3=C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)O3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HTR1A P08908 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ AKR1C3 P42330 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ GFER P55789 1/20 0.41
▸ HTR7 P34969 2/20 0.40
▸ DRD4 P21917 1/20 0.40
▸ SOD1 P00441 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873256 0.89 KDM4E (0.46) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL20873260 0.89 SMN1; SMN2 (0.42) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL20873301 0.89 DRD2 (0.36) KDM4EMAPTALDH1A1HTTTDP1
SCHEMBL20873249 0.89 DRD4 (0.39) MAPTALDH1A1HTTHTR1ADRD2
SCHEMBL21112900 0.82 MAPT (0.51) KDM4EMAPTALDH1A1HTTTDP1
SCHEMBL21112944 0.80 ALDH1A1 (0.42) KDM4EALDH1A1HTR1ADRD2HTR7
SCHEMBL20873320 0.75 ALDH1A1 (0.48) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL21112915 0.74 ALDH1A1 (0.46) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL24137896 0.69 LMNA (0.46) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL24145059 0.69 HTR7 (0.37) MEN1KMT2AKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
EP-3463480-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2019-04-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885KDM4E 4398/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885KDM4E 4398/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback